EU regulator rejects Alzheimer’s drug from Eisai and Biogen
The EU’s drugs regulator has rejected Eisai and Biogen’s Leqembi treatment for early Alzheimer’s disease, saying the risk of serious brain swelling did not outweigh its small effect on slowing cognitive decline. The decision is a blow to the companies as …